Logo

Everest's SPR206 Receives the NMPA's IND Approval for the Treatment of MDR Gram-Negative Bacterial Infections

Share this

Everest's SPR206 Receives the NMPA's IND Approval for the Treatment of MDR Gram-Negative Bacterial Infections

Shots:

  • The NMPA has approved the IND application of SPR206 (IV) for the treatment of MDR gram-negative bacterial infections. Everest will initiate the clinical program in China & results from the P-I study is expected in 2022
  • Everest got exclusive rights to develop- manufacture & commercialize SPR206 in China- South Korea- and Southeast Asian countries for the same indication under the license agreement with Spero
  • Spero has reported the results from its P-I SAD & MAD clinical trial for SPR206 which showed that the therapy is well-tolerated with no evidence of nephrotoxicity at doses within the anticipated therapeutic range for MDR gram-negative bacterial infections

  Ref: PR Newswire | Image: Everest Medicines

Click here to­ read the full press release 

Senior

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions